For the Inventor, By the Inventor

Enter assignee name

San Francisco, CA, United States of America

Neumora Therapeutics, Inc.

USPTO Granted Patents = 20

EPO Patents = 5

Trademarks = 3

Forward Citations = 7

Loading Chart...

Loading Chart...

38 inventors (with patents filed for the assignee):

Matthew Edward Kollada (6 out of 8 patents)

Tathagata Banerjee (6 out of 6 patents)

Parvez Ahammad (5 out of 16 patents)

4. Yuelu Liu (5 out of 9 patents)

5. Humberto Andres Gonzalez Cabezas (5 out of 9 patents)

6. William J Martin (5 out of 7 patents)

7. Monika Sharma Mellem (4 out of 7 patents)

8. Pablo Christian Gersberg (3 out of 4 patents)

9. Gary Brandt (3 out of 6 patents)

10. Dilinie Fernando (2 out of 13 patents)

11. Anne-Marie Beausoleil (2 out of 33 patents)

12. Robert M Jones (2 out of 85 patents)

13. Zhihua Ma (2 out of 31 patents)

14. Mariangela Urbano (2 out of 11 patents)

15. David Hardick (2 out of 6 patents)

20 patents: Sort by Forward Citations

1. 12731692 - Predicting the outcome of a clinical trial using a machine learning model (2026-09-08),

2. 12371414 - Methods of treating neurological disorders (2025-07-29),

3. 12247037 - 1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders (2025-03-11),

4. 12232848 - System and method of facial analysis (2025-02-25),

5. 12171758 - Crystalline salt forms of kappa opioid receptor antagonist and products and methods related thereto (2024-12-24),

6. 12152038 - Vasopressin receptor antagonists and products and methods related thereto (2024-11-26),

7. 12087446 - Multimodal dynamic attention fusion (2024-09-10),

8. 12002590 - Machine learning-based diagnostic classifier (2024-06-04),

9. 11993580 - Methods of treating neurological disorders (2024-05-28),

10. 11942224 - System and method for identifying transdiagnostic features shared across mental health disorders (2024-03-26),

11. 11887724 - Estimating uncertainty in predictions generated by machine learning models (2024-01-30),

12. 11858943 - Vasopressin receptor antagonists and products and methods related thereto (2024-01-02),

13. 11857322 - Systems and methods for screening, diagnosing, and stratifying patients (2024-01-02),

14. 11842793 - Methods and tools for detecting, diagnosing, predicting, prognosticating, or treating a neurobehavioral phenotype in a subject (2023-12-12),

15. 11798681 - Machine learning systems for training encoder and decoder neural networks (2023-10-24),

Neumora Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, focused on developing innovative therapies for neuropsychiatric disorders. The organization specializes in leveraging advanced neuroscience and drug development techniques to create treatments aimed at addressing unmet medical needs in mental health. By integrating cutting-edge research with a patient-centric approach, Neumora aims to transform the landscape of neurotherapeutics and improve the quality of life for individuals affected by these conditions.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

20 Patents

#240 in San Francisco, CA

#3,928 in California

#16,368 in US

#31,196 in the World

San Francisco, CA, United States of America

Neumora Therapeutics, Inc.

Forward Citations = 7

38 inventors:

Matthew Edward Kollada (6 out of 8 patents)

Tathagata Banerjee (6 out of 6 patents)

Parvez Ahammad (5 out of 16 patents)

4. Yuelu Liu (5 out of 9 patents)

5. Humberto Andres Gonzalez Cabezas (5 out of 9 patents)

Please report any incorrect information to [email protected]

Loading…